OncoMatch/Clinical Trials/NCT03907826
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Is NCT03907826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including PD-1 blocking antibody and GP for recurrent nasopharyngeal carcinoma.
Treatment: PD-1 blocking antibody · GP — This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RII, RIII, RIVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-tumor Chinese medicine treatment
Treated with anti-tumor Chinese medicine treatment
Cannot have received: PD-1 antibody or other immunotherapy for PD-1/PD-L1 pathway
Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1 pathway
Lab requirements
Blood counts
wbc count ≥ 3×10e9/l, ne count ≥ 1.5×10e9/l, hgb ≥ 90g/l, plt count ≥ 100×10e9/l
Kidney function
bun/cre ≤ 1.5×uln or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula)
Liver function
alt/ast ≤ 2.5×uln, tbil ≤ 2.0×uln
Cardiac function
nyha class 3 or 4, unstable angina, myocardial infarction within 1 year, or clinically meaningful arrhythmia that requires treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03907826 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage RII or RIII or RIVA is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages